C4 Therapeutics Appoints New Chief Medical Officer

TL;DR

C4 Therapeutics just named Dr. Adam Schlegel as CMO, effective Nov 19. Big move for their clinical strategy.

AI Summary

C4 Therapeutics, Inc. announced on November 20, 2024, that Dr. Adam R. Schlegel has been appointed as Chief Medical Officer, effective November 19, 2024. Dr. Schlegel previously served as Senior Vice President, Clinical Development at the company. This appointment is part of the company's ongoing efforts in clinical development.

Why It Matters

The appointment of a new Chief Medical Officer is a key leadership change that could signal a shift in the company's clinical strategy and development pipeline.

Risk Assessment

Risk Level: medium — Leadership changes, especially in critical roles like CMO, can introduce uncertainty regarding future strategic direction and execution.

Key Players & Entities

• C4 Therapeutics, Inc. (company) — The company filing the report.
• Dr. Adam R. Schlegel (person) — Newly appointed Chief Medical Officer.
• November 19, 2024 (date) — Effective date of Dr. Schlegel's appointment.
• November 20, 2024 (date) — Date of the report filing.
• Senior Vice President, Clinical Development (title) — Dr. Schlegel's previous role at C4 Therapeutics.

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CCCC The Nasdaq Glo

Filing Documents

• cccc-20241120.htm (8-K) — 32KB
• cccc-20241120xexx991.htm (EX-99.1) — 9KB
• c4tlogo1.jpg (GRAPHIC) — 9KB
• 0001628280-24-048593.txt ( ) — 182KB
• cccc-20241120.xsd (EX-101.SCH) — 2KB
• cccc-20241120_lab.xml (EX-101.LAB) — 22KB
• cccc-20241120_pre.xml (EX-101.PRE) — 13KB
• cccc-20241120_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On November 20 , 2024 , the Company issued a press release announcing Mr. Hoerter's appointment to the Board. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form. Exhibit Number Description 99.1 Press release issued November 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. C4 Therapeutics, Inc. Date: November 20, 2024 By: /s/ Jolie M. Siegel Jolie M. Siegel Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR